AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02448849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous injection
Description: Percutaneous implantation of placebo in patients with nonunion fracture.
Study NCT01476228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG recording
Description: EEG recording
Study NCT02823314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cure Tape™ covering T 7 and T 8 dermatomes
Description: The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.
Study NCT02823314 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cure Tape™ away from dermatomes T 7 and T 8
Description: The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
Study NCT02207335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine，Capecitabine
Description: Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
Study NCT02207335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Carboplatin
Description: Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
Study NCT04287894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: After CIT-CRT
Study NCT00390299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic Antigen-Expressing Measles Virus
Description: Given via injection into resection cavity or around tumor bed and/or IT
Study NCT00390299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00390299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo en bloc resection
Study NCT00235508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone (Lunesta)
Description: Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
Study NCT02751138 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Tumor resection
Study NCT01666704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 2mg, Once daily, 1 year
Study NCT01666704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 15mg, Once daily, 1 year
Study NCT01666704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with BMS-823778
Description: Capsules, Oral, 0mg, Once daily, 1 year
Study NCT01750866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Study NCT01750866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
Study NCT01750866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
Study NCT02665988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
Study NCT02665988 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
Study NCT03751943 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)
Description: NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
Study NCT01359436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing antibody probing system (e- Ab sensing)
Description: Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
Study NCT00433199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone (T) Gel 1.62%
Description: Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
Study NCT00433199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control
Study NCT00726544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARC 1779 Placebo
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
Study NCT00726544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1779 Injection
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
Study NCT00726544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1779 Injection
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
Study NCT00726544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1779 Injection
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
Study NCT01576952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: Bromfenac in DuraSite
Study NCT01576952 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DuraSite Vehicle
Description: DuraSite Vehicle
Study NCT02748486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training Jumping to Conclusion
Description: Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.
Study NCT02748486 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Group discussion
Description: Group discussion of current events
Study NCT02748486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training To Empathize
Description: Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
Study NCT01803139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjuvant breast radiotherapy
Description: Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
Study NCT01803139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant breast radiotherapy
Description: Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
Study NCT01763970 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Study NCT02541188 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis
Study NCT00838253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
Study NCT00838253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
Study NCT00838253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
Study NCT00838253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo continuous i.v. infusion for 24 hours
Study NCT04470401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Description: application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
Study NCT04470401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
Study NCT02359370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
Study NCT02359370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
Study NCT02093312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Home food-delivery service
Description: A home food-delivery service is offered the intervention group of cancer patients
Study NCT00371085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
Study NCT02434744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD026
Description: Dosed in combination
Study NCT02434744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed in combination
Study NCT02434744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician
Study NCT02434744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician
Study NCT03631550 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relivion active
Description: 1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation
Study NCT03631550 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Relivion Sham
Description: 1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation
Study NCT03314675 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BIOTRONIK CRT-D
Description: Pre-specified follow-up and measurements
Study NCT03062358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
Study NCT03062358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline solution administered as an IV infusion Q3W
Study NCT03256422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment discontinuation
Description: • Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir
Study NCT03256422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment discontinuation
Description: • Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir
Study NCT04161183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracoporeal shock wave therapy
Description: Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks
Study NCT04161183 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks
Study NCT04209010 — intervention group
Intervention type: PROCEDURE
Intervention: one-stage technique
Description: breast reconstruction in one stage using silicone implant and acellular dermal matrix.
Study NCT03478228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Sensory Training
Study NCT03478228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Sensory Training
Study NCT03062358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: best supportive care (BSC)
Description: BSC will include pain management and management of other potential complications including ascites per local standards of care.
Study NCT03062358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: best supportive care (BSC)
Description: BSC will include pain management and management of other potential complications including ascites per local standards of care.
Study NCT04251013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary brushing with the RX Cytology brush, Boston Scientific
Description: Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)
Study NCT04251013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary brushing with the Infinity® brush, US Endoscopy
Description: Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)
Study NCT04512651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tibiotarsal Thrust Manipulation
Description: The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.
Study NCT04512651 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Simulation Tibiotarsal Thrust Manipulation
Description: Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
Study NCT02869022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N
Description: comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
Study NCT02869022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol
Description: comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
Study NCT02869022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: organ perfusion for heart transplantation
Study NCT02869022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: organ perfusion for heart transplantation
Study NCT01170962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Film coated tablet, Oral, 20 mg, once daily, 24 weeks
Study NCT01170962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
Study NCT01170962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film coated tablet, Oral, 0mg, Once daily, 24 weeks
Study NCT01170962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
Study NCT01005706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rapamune, mycophenolate mofetil and steroid
Description: At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator.
Study NCT01170962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
Study NCT03956004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OM1 Dell Shared Decision Making Tool
Description: Decision aid meant to improve shared decision making among patients and providers.
Study NCT03956004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education material from OM1 Dell Shared Decision Making Tool
Description: Investigator-written educational material and quiz to test knowledge of osteoarthritis and treatment options.
Study NCT03887650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivicaine 1.3%
Description: 10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
Study NCT03887650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%
Description: 20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
Study NCT01503749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-colony stimulating factor
Description: G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.